

# Lourdes DomÃ- nguez-DomÃ- nguez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/487512/publications.pdf>

Version: 2024-02-01

26  
papers

397  
citations

933447

10  
h-index

752698

20  
g-index

27  
all docs

27  
docs citations

27  
times ranked

879  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. <i>Clinical Infectious Diseases</i> , 2017, 65, 2112-2118.	5.8	88
2	All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. <i>Hepatology</i> , 2018, 68, 32-47.	7.3	64
3	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw059.	0.9	34
4	Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). <i>EBioMedicine</i> , 2020, 55, 102779.	6.1	28
5	Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004-2018. <i>PLoS ONE</i> , 2021, 16, e0249864.	2.5	25
6	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 5606.	3.3	22
7	Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 738-742.	3.0	22
8	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx258.	0.9	21
9	Liver failure in human immunodeficiency virus-Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 752-753.	3.7	13
10	Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment. <i>Aids</i> , 2021, 35, 1283-1293.	2.2	13
11	Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 818-824.	2.0	10
12	Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions. <i>Frontiers in Microbiology</i> , 2019, 10, 370.	3.5	9
13	Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. <i>Liver International</i> , 2021, 41, 2885-2891.	3.9	9
14	Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 725-734.	2.9	8
15	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S8-S19.	4.0	8
16	Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3263-3271.	3.0	5
17	Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018. <i>BMC Infectious Diseases</i> , 2022, 22, 379.	2.9	5
18	HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz214.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients. Journal of Clinical Medicine, 2020, 9, 2091.	2.4	3
20	Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients. Enfermedades Infecciosas Y Microbiología Clínica, 2020, 38, 275-278.	0.5	3
21	Bloqueo de rama dependiente de frecuencia y trayecto coronario intramiocárdico: otras causas de dolor torácico. Revista Clínica Española, 2015, 215, 135-136.	0.6	1
22	HCV eradication with all-oral therapy in cirrhotic HIV-coinfected patients: an observational study of early changes in liver function and fibrosis tests. Revista Española De Enfermedades Digestivas, 2019, 111, 626-632.	0.3	1
23	Peritonitis bacteriana espontánea por Streptococcus salivarius en paciente con coinfección por VIH-VHC en tratamiento con antivirales de acción directa. Enfermedades Infecciosas Y Microbiología Clínica, 2017, 35, 199.	0.5	0
24	Streptococcus salivarius spontaneous bacterial peritonitis in a HIV/HCV-co-infected patient treated with direct antiviral agents. Enfermedades Infecciosas Y Microbiología Clínica (English Ed ), 2017, 35, 199.	0.3	0
25	Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 367-372.	0.5	0
26	Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients. Enfermedades Infecciosas Y Microbiología Clínica (English Ed ), 2020, 38, 275-278.	0.3	0